Distinct cellular source and bulk immune correlates of HAVCR2 expression in seminoma
Authors:
- Si Hyun KimSKSi Hyun Kim
- Dae Young LeeDLDae Young Lee
- Min Gyu KimMKMin Gyu Kim
- Myoung Jun JungMJMyoung Jun Jung
- Tae Woong HanTHTae Woong Han
- Hee Jo YangHYHee Jo Yang
- Doo Sang KimDKDoo Sang Kim
- Hyung Joo KimHKHyung Joo Kim
- Chang Ho LeeCLChang Ho Lee
- Youn Soo JeonYJYoun Soo Jeon
- Ji-Hye LeeJLJi-Hye Lee
- Ki Hong KimKKKi Hong Kim
- 14 November 2026
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 43 (12) , 386
Abstract
No abstract availableKeywords
Funding Information
- Soonchunhyang University
This publication has 31 references indexed in Scilit:
- HAVCR2 (TIM-3) as a favorable prognostic immune marker in seminoma: Integrative checkpoint screening and tissue validationCancer Treatment and Research Communications, 2026
- PD-L1 expression in prostate cancer and Gleason Grade Group: Is there any relationship? Findings from a multi-institutional cohort.Pathology - Research and Practice, 2025
- Phase II study of avelumab in multiple relapsed/refractory germ cell cancerInvestigational New Drugs, 2019
- Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic DataCell Systems, 2019
- An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim AnalysisEuropean Urology, 2019
- Integrated Molecular Characterization of Testicular Germ Cell TumorsCell Reports, 2018
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic ActivityCell, 2015
- Tumor-Associated Macrophages: From Mechanisms to TherapyImmunity, 2014
- Macrophage Activation and Polarization: Nomenclature and Experimental GuidelinesImmunity, 2014
- Progression‐free and overall survival in patients with relapsed/refractory germ cell tumors treated with single‐agent chemotherapy: Endpoints for clinical trial designCancer, 2011